Liver Glucokinase A456V induces potent hypoglycemia without dyslipidemia through a paradoxical induction of the catalytic subunit of glucose-6-phosphatase

dc.contributor.authorVidal Alabró, Anna
dc.contributor.authorGómez Valadés, Alicia G.
dc.contributor.authorMéndez-Lucas, Andrés
dc.contributor.authorLlorens i Baucells, Jordi
dc.contributor.authorBartrons Bach, Ramon
dc.contributor.authorBermúdez i Mas, Jordi
dc.contributor.authorPerales Losa, Carlos
dc.date.accessioned2013-12-04T10:33:08Z
dc.date.available2013-12-04T10:33:08Z
dc.date.issued2011
dc.date.updated2013-12-04T10:33:08Z
dc.description.abstractRecent reports point out the importance of the complex GK-GKRP in controlling glucose and lipid homeostasis. Several GK mutations affect GKRP binding, resulting in permanent activation of the enzyme. We hypothesize that hepatic overexpression of a mutated form of GK, GKA456V, described in a patient with persistent hyperinsulinemic hypoglycemia of infancy (PHHI) and could provide a model to study the consequences of GK-GKRP deregulation in vivo. GKA456V was overexpressed in the liver of streptozotocin diabetic mice. Metabolite profiling in serum and liver extracts, together with changes in key components of glucose and lipid homeostasis, were analyzed and compared to GK wild-type transfected livers. Cell compartmentalization of the mutant but not the wild-type GK was clearly affected in vivo, demonstrating impaired GKRP regulation. GKA456V overexpression markedly reduced blood glucose in the absence of dyslipidemia, in contrast to wild-type GK-overexpressing mice. Evidence in glucose utilization did not correlate with increased glycogen nor lactate levels in the liver. PEPCK mRNA was not affected, whereas the mRNA for the catalytic subunit of glucose-6-phosphatase was upregulated ~4 folds in the liver of GKA456V-treated animals, suggesting that glucose cycling was stimulated. Our results provide new insights into the complex GK regulatory network and validate liver-specific GK activation as a strategy for diabetes therapy.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec605091
dc.identifier.issn1687-8337
dc.identifier.pmid22194744
dc.identifier.urihttps://hdl.handle.net/2445/48277
dc.language.isoeng
dc.publisherHindawi
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1155/2011/707928
dc.relation.ispartofInternational Journal Of Endocrinology, 2011, num. 2011, p. 1-12
dc.relation.urihttp://dx.doi.org/10.1155/2011/707928
dc.rightscc-by (c) Vidal Alabró, Anna et al., 2011
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)
dc.subject.classificationGlucocinasa
dc.subject.classificationFetge
dc.subject.classificationHipoglucèmia
dc.subject.classificationTrastorns del metabolisme dels lípids
dc.subject.classificationDiabetiscat
dc.subject.otherGlucokinase
dc.subject.otherLiver
dc.subject.otherHypoglycemia
dc.subject.otherLipid metabolism disorders
dc.subject.otherDiabeteseng
dc.titleLiver Glucokinase A456V induces potent hypoglycemia without dyslipidemia through a paradoxical induction of the catalytic subunit of glucose-6-phosphatase
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
605091.pdf
Mida:
3.05 MB
Format:
Adobe Portable Document Format